quantisnow
FeedTopReportsPricing
⌘K
Live feed
06:30:00·1998d
PRRelease
Mylan N.V. logo
Bristol-Myers Squibb Company logo

Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets for Viatris

MYL· Mylan N.V.BMY· Bristol-Myers Squibb Company
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • MYL
    Mylan N.V.
    Health Care
  • BMY
    Bristol-Myers Squibb Company
    Health Care

Recent analyst ratings

  • Feb 25BMYUpdateRBC Capital Mkts$60.00
  • Feb 20BMYUpdateBarclays$75.00
  • Jan 7BMYUpdateUBS$65.00
  • Dec 15BMYUpdateBofA Securities$61.00
  • Dec 12BMYUpdateGuggenheim$62.00
  • Nov 13BMYUpdateScotiabank$45.00

Related

  • PR19h
    Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
  • PR2d
    Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion
  • PR3d
    Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
  • SEC6d
    SEC Form DEFA14A filed by Bristol-Myers Squibb Company
  • PR8d
    Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases
  • PR14d
    Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours
  • INSIDER21d
    SEC Form 4 filed by Shanahan Karin
  • INSIDER21d
    SEC Form 4 filed by Elkins David V
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022